Role of Janus Kinase inhibitors in the management of pulmonary involvement due to Long COVID-19 disease: A case control study
OBJECTIVES: Ongoing symptomatic coronavirus disease 2019 (OSC) is defined as persistent symptoms beyond 4 weeks of acute illness. OSC leads to prolonged hospitalization and oxygen dependence. We aimed to find the outcome of Janus kinase inhibitors (JAKi) as a steroid-sparing agent to treat OSC. METH...
Saved in:
Main Authors: | Pawan Kumar Singh, Vinod Kumar Sharma, Lokesh Kumar Lalwani, Dhruva Chaudhry, Manjunath B. Govindagoudar, Chaudhari Pramod Sriram, Aman Ahuja |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-07-01
|
Series: | Turkish Journal of Emergency Medicine |
Subjects: | |
Online Access: | https://journals.lww.com/10.4103/tjem.tjem_363_22 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Janus kinase inhibitors and biologics for treatment of livedoid vasculopathy: a systematic review
by: Yu Liu, et al.
Published: (2025-12-01) -
Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
by: Yachar Dawudi, et al.
Published: (2025-01-01) -
Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor
by: Ya-Chun Huang, et al.
Published: (2025-02-01) -
Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
by: Huibin Yang, et al.
Published: (2025-12-01) -
JAK inhibitors: a new choice for diabetes mellitus?
by: Mengjun Zhou, et al.
Published: (2025-01-01)